Search clinical trials for: 23VPS

Total 8 results

Pfizer

Completed

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

Pneumococcal Infections

United States
Pfizer

Completed

Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Vaccines, Pneumococcal Conjugate Vaccine

United States, Spain, France, Canada, Germany, Czechia, Sweden, Belgium, Poland, Netherlands
Pfizer

Completed

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

United States
Pfizer

Completed

Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

HIV Infections | Pneumococcal Infections

South Africa, Romania
Pfizer

Completed

A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older

Pneumococcal Vaccines | Pneumococcal Conjugate Vaccine

Japan
Pfizer

Completed

Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

HIV Infections | Pneumococcal Infections

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

Pneumococcal Vaccines

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Pneumococcal Infections

United States, Sweden

3

Subscribe